IDENTIFICATION AND QUANTITATION OF INSULIN IN THE FETAL RABBIT BRAIN. Ruben Schechter, Lynn Karycki,

Arnold Kahn and Sherin Devaskar. St. Louis Univer-sity and the Pediatric Research Institute, Cardinal 482 Glennon Children's Hospital. Dept. of Pediatrics, St. Louis, MO

It has been known for sometime that adult/neonatal rat and fetal rabbit brain contain an insulin-like substance whose precise identity, however, has remained in doubt. In an effort to clarify this issue, fetal rabbit brains (22-25-27d gestation; term 31d) were collected and either sliced for peroxidase-antiperoxidase (PAP) staining or extracted with an acid ethanol for

SDS-PA gel and ELISA determinations. The monoclonal antibody used for PAP and ELISA determinations. The monoclonal antibody used for PAP and ELISA analyses recognized insulin but not IGF-I. Brain slices stained by the PAP technique for insulin showed no reactive cells despite using antibody concentrations as high as 1:20 (pancreatic islets were positive at 1:10,000 dilution). On the other hand, iodinated brain proteins separated by SDS-PAGE and located by autoradiography revealed a protein band that co-migrated with authentic porcine insulin (Mr~6000).In addition, ELISA analysis demonstrated the presence of ~100ng of insulin per mg brain extract or 20g wet brain. This level of insulin was constant throughout the stages of fetal life studied. Why the peptide could not be detected by PAP staining remains unknown but might result from the presence of low amounts of antigen, antigen "masking" or antigen denaturation. We conclude that insulin is present in the fetal brain but in relatively minute amounts. The biologic function of the peptide within the brain remains to be studied.

GROWIH PATIERNS AND ENDOCRINE STATUS IN CHILDREN WITH OPTIC Revel hypothasia. Sanging Shu, Geoffrey P. Rednond, George R. Beauchamp, Robert P. Cruse and Gregory G. Louis (Sponsored by Paul G. Dymant) Cleveland Clinic Foundation, Depts. of 483 Endocrinology, Ochthalmology and Neurology, Cleveland, Ohio USA

Optic nerve hypoplasia (ONH) is known to be associated with hypothalamic-pituitary dysfunction including growth homone deficiency (hGH-D), panhypopituitarism and diabetes insipidus (DI). Previous series have focused on specific subgroups and probably did not include the full range of patients with QNH.

We have examined growth and endocrine data on 66 subjects (38M, 28F) with ONH aged 1 to 33 yrs (mean 9.5 ± 7.3 yrs). Several distinct patterns of growth and endocrine function were found: 1) Normal height arbitrarily defined as rank \geq 5% ile was present in 68%. All 7 adults were in this group demonstrating that at least some with ONH achieve normal adult height. 2) Growth failure occurred in 21 subjects (32%). Its criset was 2 years in 10/21, GROWTH failure coolined in 21 subjects (3.6.). Its creatives 2 years in 10/21, between 2 and 3 years in 4/21, and unknown in 7/21. This age of creating younger than reported by G. Ostin, et al. Growth homone therapy was able to normalize the growth in 2 subjects. Among this subgroup 6/21 were hypothyroid, 8/21 had definite cortisol deficiency and 3/21 had spontaneous hypothyroid, 8/21 had definite cortisol deficiency and 3/21 had spontaneous hypothyroid, 8/21 had definite cortisol deficiency and 3/21 had spontaneous was present in 11% of subjects. Two additional abnormal growth patterns were noted. 3) Early or precocious puberty coursed in 4/21 growth deficient children, supporting the observation of C.A. Huseman, et al. 4) Progressive obesity and normal growth with hGH-D similar to craniquaryngiona occurred in 2 subjects.

Conclusions: 1) Children with ONH should be followed carefully for emergence of growth and endocrine abnormalities from infancy. 2) A brief period of normal growth associated with puberty or chesity should not mislead the physician into assuming later growth will be normal.

> USEFULNESS OF THYROTROPIN BINDING INHIBITORY IMMUNO-GLOBULIN (TBII) MEASUREMENT IN CONGENITAL HYPOTHYROID-

 1484 ISM. Dorothy I. Shulman, Jack A. Strzelecki, Barry B. Bercu, Allen W. Root. University of South Florida College of Medicine, All Children's Hospital, Dept. of Pediatrics, St. Petersburg, FL 33731.
Seven infants with congenital hypothyroidism (TSH 12-603 uIU/ ●484


mL) and their mothers were screened for TBII. Two siblings with transient congenital hypothyroidism (T4-6.3, 6.9 ug/dL; TSH-397, 211 uIU/mL) were found to have significant elevation of serum TBII index (90,100;n1<10) at birth equal to that measured in the mother's serum. Technetium scan in the first-born child at 14 days revealed no thyroid gland. Repeat scan at 2 years after withdrawing thyroxine therapy was normal. In light of presumed maternal antibody-mediated hypothyroidism in the first child, hypothyroidism was predicted correctly in the second child and thyroxine therapy initiated on day 1 of life. In contrast, mild elevation of TBII index (12,13) was found in serum of two additional infants but not in maternal serum (TBII (1,7) suggesting that elevated TSH concentrations might be crossreacting in the TBII assay in these two infants. Twelve additional children (11-primary hypothyroidism, 1-thyroid hormone resistance) with elevated TSH concentrations (12-1355 uIU/mL) were tested for TBII. Four were positive (TBII 13-21). TBII correlated significantly with TSH concentrations (r=0.73, p<01). TSH concentrations (100 uIU/mL were not associated with a positive TBII. TBII may prove useful in screening infants with congenital hypothyroidism caused by maternal TSH-blocking antibodies. However, since high concentrations of TSH may crossreact in this assay maternal serum should be simultaneously assessed.

ATYPICAL 11 6-HYDROXYLASE DEFICIENCY: ABSENCE OF RENIN SUPPRESSION AND HYPERTENSION DESPITE HIGH DOC.

485 <u>Phyllis W. Speiser</u>, <u>Robin L. Nemery</u>, <u>Diane Chow</u>, <u>Kumiko O. Martin, <u>Maria I. New</u>, The New York Hospital-Cornell Medical Center, Department of Pediatrics, New York, NY 10021. Congenital adrenal hyperplasia due to 118-hydroxylase</u>

(11β -OHase) deficiency usually produces hypertension and virilization. The hormonal profile is typified by elevated serum and urinary DOC and compound S, and suppressed renin (PRA) and aldosterone (aldo). We report 2 cases in which extreme elevation of serum and urinary precursors of 11β -OHase produced neither hypertension nor suppression of PRA and aldo. These finding correlated with low purpose of pinzalogatic action in the finding of the set of the s findings correlated with low number of mineralocorticoid binding findings correlated with low number or <u>mumeratocorrelation printing</u> <u>sites per cell (MRBS)</u> in peripheral blood leukocytes. DOC suppressed following dexamethasone administration, and additional DOC infusion caused transient hypertension and expected renin suppression. We postulate that down-regulation of MRBS is an adaptive response to high DOC, inhibiting <u>response to high DOC</u>, inhibiting mineralocorticoid effects. Normal basal aldo levels indicate intact glomerulosa $ll\beta$ -hydroxylation, suggesting a defect in tissue-specific expression of the enzyme, rather than a structural gene defect.

				1	<u>ng/dl)</u>				
BASAL		BP	:	DOC	S	ALDO	:	PRA	MRBS
Pt 1	(7yM)	100/60	:	2045	567	22	:	15	90
Pt 2	(12yF)	92/54	:	120	3150	29	:	11	
Mean	Normal	100/65	:	20	80	9	:	<8	200



ACQUISITION OF ALDOSTERONE BIOSYNTHETIC CAPACITY IN CONGENITAL ADRENAL HYPERPLASIA WITH HOMOZYGOUS DELETION OF THE GENE WITH HOMOZYGOUS DELETION OF THE GENE (DELETION OF THE GENE), DELETION OF THE GENE (DELETION OF THE GENE), DELETION OF THE GENE (DELETION OF THE GENE), DELETION OF THE GENE), DELETION OF THE GENE (DELETION OF THE GENE), DELETION OF THE GENE), DELETION OF THE GENE (DELETION OF THE GENE), DELETION OF THE GENE), DELETION OF THE GENE (DELETION OF THE GENE), DELETION OF THE GENE (DELETION), DELETION, DEL

INSULIN-LIKE GROWTH FACTOR-II (IGF-II) RECEPTORS IN ▲ 487 INSULIN-LIKE GROWTH FACTOR-II (IGF-II) RECEPTORS IN RAT NEUROBLASTOMA CELLS. <u>Marlene A. Sturm</u>, <u>Hung Pham</u>, and <u>Ron G. Rosenfeld</u>. Stanford University School of Medicine, Department of Pediatrics, Stanford, CA. The presence of high concentrations of IGF-II in cerebrospinal fluid and brain, as well as the promin-ence of receptors in cortical tissues, make the CNS an attractive site for the study of IGF-II binding and action. B-104 is a transformed rat neuroblastoma cell line whose neuronal qualities include neurotransmitter synthesis and the ability to project avo-

transformed rat neuroblastoma cell line whose neuronal qualities include neurotransmitter synthesis and the ability to project axo-dendritic processes. We observed steady-state binding of 125-I-IGF-II to B-104 membranes between 1.5 and 4 hrs at optimal cond-itions of 25°C, pH 7-8. Specific binding averaged 12.244.0% per 100 ug/ml membrane protein, compared with 125-I-IGF-I binding of 10.1±2.9%. 125-I-IGF-II binding was minimally inhibited (<20%) by insulin concentrations as high as 100 ug/ml. In the presence of unlabeled IGF-II (0.5-5ng/ml), 125-I-IGF-II binding was increased by as much as 50% over baseline: at higher concentrations. 125-I by as much as 50% over baseline; at higher concentrations, 125-I-IGF-II binding was inhibited, with 50% displacement at 50 ng/ml. We observed a similar increase in 125-I-IGF-II binding in the presence of unlabeled IGF-I at concentrations ranging from 1-400 presence of unlabeled LGF-I at concentrations ranging from 1-400 ng/ml. When 125-I-IGF-II was cross-linked to membranes, solubil-ized, and immunoprecipitated with a specific antibody for the rat IGF-II receptor, a classical type II receptor (Mr~240K) was visualized upon electrophoresis. These results demonstrate the presence in B-104 cells of a specific high affinity type II receptor, as well as a membrane-bound binding protein, whose existence in conditioned medium was confirmed by activated charcoal assay. B-104 should serve as an appropriate and intriguing in vitro model for future study of IGF receptors and action in the CNS.